Aclaris Therapeutics (ACRS) reported Q4 Revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 Revenue for the quarter came in at $9.21 million versus the consensus estimate of $2.08 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Ferrari names new chief marketing officer, effective July 2026